The hemophilia market is anticipated to grow at a CAGR of 6.0% during the forecast period. Hemophilia is a type of inherited bleeding disorder in which the patient experiences difficulty in the natural blood clotting process of the body after an injury. Hemophilia is a genetic disorder in general, however, in rare cases, patients can develop hemophilia later in life. The general treatment of hemophilia involves the replacement of the missing blood clotting factor which is done by infusing commercially prepared factor concentrates. The hemophilia is diagnosed by certain blood tests, clotting factor tests, also called factor assays done by the trained physicians. 

Increasing access to its diagnosis is anticipated to fuel the growth of the hemophilia market. Moreover, the overall improvement in the hemophilia patient care system in recent years will significantly fuel the growth of the market. However, the high cost associated with the therapies and drugs used for the treatment is anticipated to hamper the growth of the hemophilia market. Moreover, in the upcoming period, the chances of the introduction of biosimilar are very few. Due to this, no significant drop in drug costs can be expected during the forecast period. Besides, the negative impacts of plasma-derived products on the health of the patient will also lower the adoption of plasma therapy for the treatment. In addition, as hemophilia is a rare disease, it is quite challenging for the companies to find patients to rollout in the clinical trials for new drugs of hemophilia. 

Segmental Outlook 

The global hemophilia market is segmented based on type, therapy, and product type. Based on the type, the market is sub-segmented into hemophilia A, hemophilia B, and others. Based on the therapy, the market is sub-segmented into replacement therapy, gene therapy, and others. Further, based on the product type, the market is bifurcated into recombinant coagulation factor concentrates and plasma-derived coagulation factor concentrates.

The hemophilia A segment will hold the major market share 

The hemophilia A segment is anticipated to hold a major market share all across the globe. hemophilia A is also known as classic hemophilia is caused by the missing or defective clotting protein called factor VIII. According to the Center for Disease Control and Prevention (CDC) hemophilia A is about four times as common as hemophilia B, and about half of those suffering from hemophilia A have a severe form of it which is expected to provide a considerable market share during the forecast period. 

Global Hemophilia Market Share by Type, 2019 (%)

Regional Outlooks

The global hemophilia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the hemophilia market during the forecast period. The high cost of treatment and the ability to expend that much amount is the key reason for the significant market share of the region. In the US, the treatment cost of hemophilia can reach up to $1 million in some cases. High insurance coverage and a high diagnosis rate are also supporting the significant market share of the region. Moreover, the strong presence of key market players with the continuous expansion of their product portfolio is also anticipated to drive the hemophilia market across the region.

Global Hemophilia Market Growth, by Region 2020-2026

Asia-Pacific will augment with the lucrative growth rate in the hemophilia market 

Asia-Pacific is anticipated to show the lucrative growth rate in the hemophilia market owing to the increasing awareness and diagnosis of hemophilia across the region. Additionally, the increasing access of patients to the technologically advanced therapies and drugs is also increasing in the region. Moreover, the surge in medical research activities across the region will also fuel the growth of the hemophilia market in the Asia-Pacific region. However, the high cost of treatment is a major factor hampering the market growth in the region. The World Federation of Hemophilia (WFH) provides treatment of hemophilia in the emerging economies all across the globe. By 2019, 73 countries were receiving assistance from WFH and around 19,800 patients have been treated from the organization. Major countries receiving assistance include China, India, ASEAN, Argentina, Mexico, and so on.  

Market Players Outlook

The hemophilia market is a consolidated market. The key players of the Hemophilia market include Baxter International, Inc., BioMarin Pharmaceutical Inc., CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market. 

Recent Activities

• In June 2020, CSL Behring announced the acquisition of a licensing agreement of $450 million with uniQure N.V. The license agreement has provided the company with the rights to commercialize hemophilia B gene therapy AMT-061. The agreement will enable the company to bring a hemophilia B gene therapy to market opposite to the companies including Pfizer.
• In February 2020, BioMarin Pharmaceutical Inc.’s Valrox, gene therapy for Hemophilia A got acceptance from the US FDA for the priority review.
• In May 2020, Bayer AG formed a five-year alliance with the World Federation of Hemophilia Humanitarian Aid Program. The alliance will enable the company to deliver training, education, and treatments to healthcare professionals in more than 60 underserved countries across the globe.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Hemophilia market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.